FEDERALhearing transcript

High Impact

Senate Hearing on FDA User Fee Programs

Original title: FDA USER FEE AGREEMENTS: ADVANCING MEDICAL PRODUCT REGULATION AND INNOVATION FOR THE BENEFIT OF PATIENTS

January 1, 2023

FDA medical regulation user fees healthcare innovation drug safety medical devices

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The of these programs determines the FDA's funding levels and regulatory capacity for reviewing new medical products, which directly impacts the speed and safety of bringing new treatments to market.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medical product manufacturers

These companies pay user fees to the FDA to support the regulatory review process for their products.

FDA

The agency relies on these fees as a significant portion of its operating budget for product reviews and inspections.

Patients

Patients are affected by the speed and safety standards applied to the medical products they use.

What changed

Last recorded activity January 1, 2023.

What's next

Next step not available in the current record.

Summary

The Senate Committee on Health, Education, Labor, and Pensions held a hearing to discuss the of four Food and Drug Administration (FDA) user fee programs. These programs allow the FDA to collect fees from medical product companies to fund the review and regulation of drugs, devices, and other medical products.

Key Facts

The hearing focused on the reauthorization of four distinct FDA user fee programs.
User fee programs allow the FDA to collect funds from industry to support the review of medical products.
The FDA is responsible for regulating approximately 80 percent of the U.S. food supply.
The FDA conducts inspections of thousands of food, drug, and device manufacturing sites annually.
The committee received testimony from representatives of the healthcare industry, medical device manufacturers, and policy research organizations.
The hearing included a review of in-person medical product inspection counts from fiscal years 2017 to 2021.
The committee accepted written responses to questions from Senators regarding the user fee agreements.

Frequently Asked Questions

What are FDA user fee programs?

These are agreements where the FDA collects fees from companies that manufacture medical products to help fund the agency's regulatory and review processes.

Why does the Senate need to reauthorize these programs?

The programs are time-limited and require periodic Congressional approval to continue collecting and spending these industry-provided funds.

Why It Matters

The of these programs determines the FDA's funding levels and regulatory capacity for reviewing new medical products, which directly impacts the speed and safety of bringing new treatments to market.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Inspection Data

The inclusion of specific inspection counts from FY17 to FY21 suggests a legislative focus on the FDA's oversight performance during the pandemic era.

Food and Drug Administration Richard Burr

Connected Entities

personMark Leahey“Witness from Medical Device Manufacturers Association”Map →

personLiz Richardson“Witness from The Pew Charitable Trusts”Map →

personDavid Gaugh“Witness from Association for Accessible Medicines”Map →

personCartier Esham“Witness from Biotechnology Innovation Organization”Map →

organizationFood and Drug Administration“The federal agency responsible for regulating food and medical products”Map →

personRichard Burr“Ranking Member of the Senate HELP Committee”Map →

personPatty Murray“Chair of the Senate HELP Committee”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance80
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz10
Current news / social attention level

Publisher tools